ReviewKidney international reports2022
Renal Sympathetic Denervation for Hypertension.
Review in Kidney international reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- The importance of cross-talk in research and the body: An early career researcher perspective.Experimental physiology · 2026Article
- Review
- Norepinephrine promotes oxidative stress in vascular adventitial fibroblasts via PKC/NFκB-mediated NOX2 upregulation.Redox report : communications in free radical research · 2025Article
- Aorticorenal ganglion ablation for blood pressure lowering in canine models.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Nomogram for Predicting Postoperative Blood Pressure Reduction in Hypertensive Patients: A Single-Center Retrospective Study.International journal of medical sciences · 2025Article
- Revisiting sex as a biological variable in hypertension research.The Journal of clinical investigation · 2024Review
- The Efficacy of Renal Denervation in Treating Resistant Hypertension: A Systematic Review.Cureus · 2024Review
- The feasibility, efficacy, and safety of RDN procedure using COHypertension research : official journal of the Japanese Society of Hypertension · 2024Observational
- The Sympathetic Nervous System in Hypertensive Heart Failure with Preserved LVEF.Journal of clinical medicine · 2023Review
- Review
- Sequential afferent and sympathetic renal denervation impact on cardiovascular and renal homeostasis in the male Sprague-Dawley rat.Life sciences · 2023Article
- Sympathetic Denervation and Pharmacological Stimulation of Parasympathetic Nervous System Prevent Pulmonary Vascular Bed Remodeling in Rat Model of Chronic Thromboembolic Pulmonary Hypertension.Journal of cardiovascular development and disease · 2023Article
- Renal Sympathetic Hyperactivity in Diabetes Is Modulated by 5-HTInternational journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arterial hypertension is the most prevalent global modifiable risk factor for cardiovascular morbidity and mortality. Despite the availability of numerous pharmacologic treatments, many patients do not achieve guideline-recommended blood pressure targets. Therefore, renal sympathetic denervation (RDN), a process in which catheter-directed techniques are used to ablate portions of the renal artery to reduce sympathetic activity, has been extensively investigated as a complementary and nonpharmacologic approach for the treatment of arterial hypertension. This review seeks to discuss the pathophysiological rationale of this strategy, to survey its history and development, and to highlight the current clinical evidence and possible future directions of its employment. In sum, RDN has demonstrated itself to be a safe and well-tolerated endovascular intervention that can reliably contribute to improved blood pressure control and, perhaps ultimately, significant cardiovascular prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.